 | |
| Clinical data | |
|---|---|
| Other names | D-Alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide |
| Routes of administration | Oral, intravenous |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C45H55N9O6 |
| Molar mass | 817.992 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pralmorelin (INN) (brand nameGHRP Kaken 100; former developmental code namesKP-102,GPA-748,WAY-GPA-748), also known aspralmorelin hydrochloride (JAN) andpralmorelin dihydrochloride (USAN), as well as, notably,growth hormone-releasing peptide 2 (GHRP-2), is agrowth hormone secretagogue (GHS) used as adiagnostic agent that is marketed byKaken Pharmaceutical inJapan in a single-dose formulation for the assessment ofgrowth hormone deficiency (GHD).[1][2][3]
Pralmorelin is anorally-active,syntheticpeptidedrug, specifically, ananalogue ofmet-enkephalin, with theamino acid sequenceD-Ala-D-(β-naphthyl)-Ala-Trp-D-Phe-Lys-NH2.[2][4] It acts as aghrelin/growth hormone secretagogue receptor (GHSR)agonist, and was the first of this class of drugs to be introduced clinically.[2][3] Acute administration of the drug markedly increases the levels ofplasmagrowth hormone (GH)[4][5] and reliably induces sensations ofhunger and increasesfood intake in humans.[6]
Pralmorelin was also under investigation for the treatment of GHD andshort stature (pituitary dwarfism), and made it tophase IIclinical trials for these indications, but was ultimately never marketed for them.[4] This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals.[4]
 | Thishormonal preparation article is astub. You can help Wikipedia byexpanding it. |
